Dnoclast (denosumab biosimilar) / Abbott - LARVOL DELTA

Budget Impact of Switching to Biosimilar Denosumab for the Prevention and Management of Sres (IASLC-WCLC 2026) - "Conclusions : The introduction of denosumab biosimilars into the private healthcare system supports optimized resource utilization over time maintaining efficacy and safety comparable to the reference product. This could facilitate the reinvestment into expanding patient access."

HEOR • Hematological Malignancies • Multiple Myeloma • Solid Tumor

Osteoporosis treatment with biosimilars in Malaysia and Thailand: a budget impact analysis. (PubMed, Arch Osteoporos) - "The introduction of biosimilar denosumab in Malaysia and Thailand could yield significant cost savings and enhance access to biologic therapies for postmenopausal women with osteoporosis. The inclusion of biosimilar denosumab in national osteoporosis management programs could lead to increased uptake, but it is not explored in this analysis and requires further consideration."

HEOR • Journal • Osteoporosis • Rheumatology

A Multidisciplinary Approach to Addressing Barriers in Osteoporosis Screening, Diagnosis, Therapy Sequencing, and Adherence in India. (PubMed, Cureus) - "Risk stratification and imaging are key to guiding individualized treatment with antiresorptive agents such as denosumab and/or anabolic agents like teriparatide. With this background of special circumstances in Indian settings, a three-level care model is proposed, featuring community-level screening by primary care teams, diagnosis and initial treatment by specialists, and complex-case management centers with integrated support from allied healthcare professionals and community health workers. Implementing this stratified, multidisciplinary protocol has the potential to bridge existing gaps in osteoporosis care."

Journal • Review • Diabetes • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology